News Muncher - searching for received

Zydus Cadila has received emergency use approval from the Indian regulator for the use of its anti-viral drug 'Virafin'. Pharma giant Zydus says 91.15 per cent of adult patients treated with Virafin tested negative using RT-PCR in seven days. Virafin helps body cope with Interferon Alpha deficiency In its Phase III clinical trials, researchers found that a higher proportion of …

Zydus Cadila's Pegylated Interferon alpha-2b drug, 'Virafin', has received Emergency Use Approval from DCGI, the Drugs Controller General of India. Pharma giant Zydus Cadila says its anti-viral drug Virafin can not only reduce the need for medical oxygen but also improve recovery time among Covid-19 patients. Earlier launched as PegiHep, the drug was being used to treat Hepatitis C. A …

Gujarat-based drug manufacturer Zydus Cadila today said it has received approval from the Drugs Controller General of India to conduct Phase 3 clinical trials on its re-purposed drug that it hopes to use for Covid-19 treatment. The drug, Pegylated Interferon alpha-2b, 'PegiHepTM', is an approved drug that been in use since 2001 and is now being re-purposed to treat Covid-19 …

Hospitalised COVID-19 patients who received an inhaled form of an immune system protein were less likely to develop severe symptoms, according to a new study which may lead to a new treatment strategy against the disease. In the new study a formulation of interferon beta called SNG001 was directly delivered to the lungs via inhalation and its safety and efficacy …

Received